Abstract:The off-label use of racemic ketamine and the FDA approval of (S)-ketamine are promising developments for the treatment of depression. Nevertheless, racemic ketamine and (S)-ketamine are controlled substances with known abuse potential and their use is associated with undesirable side effects. For these reasons, research efforts have focused on identifying alternatives. One candidate is (2R,6R)-hydroxynorketamine ((2R,6R)-HNK), a ketamine metabolite that in preclinical models lacks the dissociative and abuse properties of ketamine while retaining its antidepressant-like behavioral efficacy. (2R,6R)-HNK's mechanism of action however is unclear. The main goals of this study were to perform an in-depth pharmacological characterization of (2R,6R)-HNK at known ketamine targets, to use target deconvolution approaches to discover novel proteins that bind to (2R,6R)-HNK, and to characterize the biodistribution and behavioral effects of (2R,6R)-HNK across several procedures related to substance use disorder liability. We found that unlike (S)- or (R)-ketamine, (2R,6R)-HNK did not directly bind to any known or proposed ketamine targets. Extensive screening and target deconvolution experiments at thousands of human proteins did not identify any other direct (2R,6R)-HNK-protein interactions. Biodistribution studies using radiolabeled (2R,6R)-HNK revealed non-selective brain regional enrichment, and no specific binding in any organ other than the liver. (2R,6R)-HNK was inactive in conditioned place preference, open-field locomotor activity, and intravenous self-administration procedures. Despite these negative findings, (2R,6R)-HNK produced a reduction in immobility time in the forced swim test and a small but significant increase in metabolic activity across a network of brain regions, and this metabolic signature differed from the brain metabolic profile induced by ketamine enantiomers. In sum, our results indicate that (2R,6R)-HNK does not share pharmacological or behavioral profile similarities with ketamine or its enantiomers. However, it could still be possible that both ketamine and (2R,6R)-HNK exert antidepressant-like efficacy through a common and previously unidentified mechanism. Given its pharmacological profile, we predict that (2R,6R)-HNK will exhibit a favorable safety profile in clinical trials, and we must wait for clinical studies to determine its antidepressant efficacy.

Exploring the Molecular Targets for the Antidepressant and Antisuicidal Effects of Ketamine Enantiomers by Using Network Pharmacology and Molecular Docking

Combining bioinformatics, network pharmacology and artificial intelligence to predict the target genes of S-ketamine for treating major depressive disorder

Differentially regulated targets in the fast-acting antidepressant effect of (R)-ketamine: A systems biology approach

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites

Probing the Membrane-Access Pathway of NMDA Receptors with Ketamine Enantiomers

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review

Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression

Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research

Mechanisms of ketamine action as an antidepressant

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions

Is the antidepressant effect of ketamine separate from its psychotomimetic effect? A review of rodent models

Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search

Uncovering the Underlying Mechanisms of Ketamine As a Novel Antidepressant